NOTE: To place order using Credit Card, P-Card, or Purchase Order – please choose kit size above and click “Add to cart” button. You can place order online without creating an account.
Transfection Reagent for NCI-N87 Cells (Gastric Carcinoma Cells, CRL-5822)
Two component formulation enhances lipid mediated transfection efficiency
Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
Kit includes Transfection Enhancer reagent and recommended transfection protocol
High transfection efficacy in the presence of serum
Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
Reproducible transfection results
Works well for standard reverse transfection and high-throughput applications
- Download NCI-N87 CRISPR/Cas9 transfection protocol: [PDF]
- Download PowerPoint presentation for NCI-N87 cells transfection kit: [PPT]
Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 91% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems NCI-N87 Transfection Protocol: [PDF]
Download MSDS: [PDF]
NCI-N87 Cell Line:
According to the American Cancer Society (ACS), gastric cancer was the most common cause of cancer fatalities in the United States until the late 1930s. However, in less developed countries with a general lack of access to refrigerated food storage, it remains a high mortality disease. Human tumor cell lines have proven to be invaluable models for studying cancer causes and properties. The NCI-N87 epithelial cell line was established from the stomach tissue of a male patient with gastric carcinoma, also known as stomach cancer. NCI-N87 cells have been derived from a metastatic site located in the liver. Also, the NCI-N87 cell line has been tested positive for myc and ERBB2 oncogenes. NCI-N87 cells express carcinoembryonic antigen (CEA) and TAG 72 surface glycoproteins. They were also found to express receptors for muscarinic cholinergic agents. In addition to being used in stomach cancer research, the NCI-N87 cell line is highly utilized in transfection. Commercially available transfection reagent kits can be ordered from Altogen Biosystems, including a two-component formulation NCI-N87 transfection reagent for gastric carcinoma cells.
Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into NCI-N87 cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).
Figure 2. Protein expression of Lamin A in NCI-N87 cells. DNA plasmid expressing Lamin A or siRNA targeting Lamin A were transfected into NCI-N87 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems provides preoptimized transfection products for life science research applications. Transfection protocols are optimized for individual cancer cell lines. Altogen Biosystems developed two types of in vivo delivery kits for animal research: Tissue-targeted reagents (delivery to liver, pancreas, and kidney tissues), and broad range in vivo delivery reagents (PEG-Liposome, Nanoparticle-based, Lipid-based, and Polymer-based kits). Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, RNA, and any other negatively charged molecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #6870)
- 1.5 ml (Catalog #6871)
- 1.5 ml CRISPR (Catalog #2183)
- 8.0 ml (Catalog #7072)